RUBY - Rubius Therapeutics doses first patient in RTX-240 cancer study

Rubius Therapeutics (RUBY) announces that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination with Merck's KEYTRUDA (pembrolizumab) for the treatment of patients with relapsed/refractory or locally advanced solid tumors. The trial is an open label, multicenter, multidose, first-in-human dose-escalation and expansion study designed to determine the safety and tolerability, pharmacokinetics, maximum tolerated dose and a recommended Phase 2 dose and dosing regimen of RTX-240.RTX-240 is designed to broadly stimulate the immune system by activating and expanding both natural killer ((NK)) cells and T cells to generate a potent anti-tumor response.Shares up more than 2% post market.

For further details see:

Rubius Therapeutics doses first patient in RTX-240 cancer study